Drug Trial Radar · NCT05761431
A Single-dose Study of Octreotide Injection in Healthy Adult Subjects
Last checked: Nov 20, 2026Latest source record: Oct 10, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
56
Actual
Start
Mar 2, 2023
Primary completion
Jun 28, 2023
Study completion Jun 28, 2023
Sponsor
- Lead sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 9, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 22 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a single-centre, single-dose, dose-escalation, placebo and positive drug-controlled Phase I clinical study in healthy Chinese subjects to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic profile of octreotide injection in healthy Chinese subjects.
Conditions
- Acromegaly
Interventions
SYHX2008 injectionDrug
Subcutaneous administration on Day 1.
Octreotide Acetate Microspheres for Injection injectionDrug
Intramuscular administration on Day 1.
Sandostatin ® injectionDrug
Subcutaneous administration on Day 1.
Placebo to SYHX2008 injectionDrug
Subcutaneous administration on Day 1.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of adverse eventsTime frame: Throughout the study period, with an average of 60 days.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Anzhen Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.